575 related articles for article (PubMed ID: 34401884)
1. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.
Puranik A; Lenehan PJ; Silvert E; Niesen MJM; Corchado-Garcia J; O'Horo JC; Virk A; Swift MD; Halamka J; Badley AD; Venkatakrishnan AJ; Soundararajan V
medRxiv; 2021 Aug; ():. PubMed ID: 34401884
[TBL] [Abstract][Full Text] [Related]
2. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.
Pawlowski C; Lenehan P; Puranik A; Agarwal V; Venkatakrishnan AJ; Niesen MJM; O'Horo JC; Virk A; Swift MD; Badley AD; Halamka J; Soundararajan V
Med; 2021 Aug; 2(8):979-992.e8. PubMed ID: 34223401
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system.
Ioannou GN; Locke ER; Green PK; Berry K
EClinicalMedicine; 2022 Mar; 45():101326. PubMed ID: 35261970
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection.
Puranik A; Lenehan PJ; Silvert E; Niesen MJM; Corchado-Garcia J; O'Horo JC; Virk A; Swift MD; Gordon JE; Speicher LL; Geyer HL; Kremers W; Halamka J; Badley AD; Venkatakrishnan AJ; Soundararajan V
Med; 2022 Jan; 3(1):28-41.e8. PubMed ID: 34927113
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.
Bouillon K; Baricault B; Botton J; Jabagi MJ; Bertrand M; Semenzato L; Le Vu S; Drouin J; Dray-Spira R; Weill A; Zureik M
BMJ Med; 2022; 1(1):e000104. PubMed ID: 36936561
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
medRxiv; 2021 Oct; ():. PubMed ID: 34642696
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.
Dickerman BA; Gerlovin H; Madenci AL; Kurgansky KE; Ferolito BR; Figueroa Muñiz MJ; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
N Engl J Med; 2022 Jan; 386(2):105-115. PubMed ID: 34942066
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
10. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico.
Robles-Fontán MM; Nieves EG; Cardona-Gerena I; Irizarry RA
Lancet Reg Health Am; 2022 May; 9():100212. PubMed ID: 35229081
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies.
Chang S; Liu H; Wu J; Xiao W; Chen S; Qiu S; Duan G; Song H; Zhang R
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335101
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
[TBL] [Abstract][Full Text] [Related]
14. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
15. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Perl Y; Weng C
JMIR Public Health Surveill; 2022 May; 8(5):e35311. PubMed ID: 35486806
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Vaccine Effectiveness during the Delta Phase of the COVID-19 Pandemic in the Medicare Population Supports a Multilayered Prevention Approach.
Experton B; Elena A; Hein CS; Nordenberg D; Walker P; Schwendiman B; Burrow CR
Biology (Basel); 2022 Nov; 11(12):. PubMed ID: 36552210
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
